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steroids  [6-9], hyaluronic acid  (HA)  [10, 11], platelet-
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ticular HA  injections  receive  low strength  recommen-
dations  from  the OARSI  [19]  and  the EULAR  [20], 
but should not be used according to the Royal College 
of Physicians [16] and the AAOS [17]. Intra-articular 
PRP  injections  were  only  considered  by  the  AAOS, 
though  evidence  was  considered  to  be  insufficient  to 






products. For  example,  none of  the  guidelines makes 
any clear distinction between the different formulations 
of HA, thereby possibly reducing the perceived impact 
of  these products  on  the management  of OA. Lastly, 
information on the optimal setting for IA injections is 





cians who have a high  level of expertise  in  the use of 
such injections.
The  Delphi  method  is  a  process  designed  to  reach 
a  consensus  and develop  group decisions  in health  re-
search [22]. The basic principles of the Delphi method 











of  Italian  clinicians  who  represent  different  scientific 
societies,  are  involved  in  the management  of OA pa-
tients and have a high level of expertise in IA injection 




OA,  to  obtain  opinion-based  recommendations  to  be 
used in daily clinical practice. 
MAterIALS AND MethODS
The Delphi method was  used  to  conduct  this  con-
sensus initiative. A committee of 10 experts from Ital-
ian  universities,  public  hospitals,  territorial  services, 
research institutes and patient associations was set up. 
A  panel  composed  of  a  university  physiatrist  (VS),  a 
physiatrist  representing the Italian Society of Physical 
Medicine  and  Rehabilitation  (SIMFER)  (SB),  an  or-
thopedist representing the Italian Society of Orthope-
dics and Traumatology (FC), a radiologist representing 
the  Italian Society  of Medical Radiology  (Alb Bel),  a 
general practitioner representing the Italian Society of 
General Medicine  (OB),  a  pharmacologist  represent-
ing the Italian Society of Pharmacology (APC), a geri-
atrician (MF), an expert in pharmacoeconomics (LM), 
a  rheumatologist  representing  the  Italian  Society  of 
Rheumatology (AM) and a representative of a patient 
association  (UV)  formed  the  Consensus  Board.  The 
Consensus Board  reviewed  the  literature  and,  on  the 
basis  of  the  drugs/medical  devices  currently  available 
in  Italy  for  IA  injection  therapy,  developed  the  first-
round questionnaire (Q1). Technical support regarding 
the questionnaire design, data analysis and interpreta-
tion of  the  results was provided by  two public  health 
researchers and  two university  researchers  in Physical 
























perts  agreed  or  disagreed.  In  order  to  determine  the 
consensus  level,  the  answers  to  each  question  were 
grouped  into  three  tertiles  according  to  the  Likert-
scale scores (1-2-3: disagreement; 4-5-6: neutral; 7-8-9: 
agreement). For the purposes of this study, we consid-
ered  the  consensus  level  as  good  (a  recommendation 
can  be  made),  for  both  “agreement”  and  “disagree-






and a  shared  recommendation was not made. All  the 
items in which consensus was weak (i.e. 50-65% of an-
swers) were included again in a second-round question-


































exception  of  the  question  on  the  region  of  residence 
(answered by 32/52 experts). Both the descriptive and 
the Delphi analyses were,  therefore, conducted on 52 




comprised 25  (48%) orthopedists,  14  (26.9%) physia-




in OA treatment, with 22  (22/35: 62.8%)  stating  that 





By  analyzing  data  from  both  questionnaires,  the 
Questionnaire round 1
Response 52/111 experts, analysis of ratings and agreement 
(consensus on 98/167, threshold for consensus = 66%)  
Questionnaire round 2
Based on the first questionnaire. Items on which consensus was reached or < 50% were not repeated. 
Response 52/52 experts, analysis of ratings and agreement (consensus on 8/32), identifying items for consensus meeting    
Consensus Board meeting 
Sapienza University, Rome, 5th  February 2015
Consensus reached on all items 
Final approval
Summary of questionnaires, meeting conclusions and consensus sent to all Consensus Board
members for final approval 
Kick off Consensus Board 
25 June 2014
Sapienza University, Rome, 25th  June 2014
Group of experts’ formation
Email invitations: 136 sent 
(111 participating, 25 no response) 
Questionnaire  design 
Literature review by Consensus Board 
(167 items in four categories: treatment 
indications, drug/medical device choice, 
treatment efficacy, setting); general info
Figure 1 
Flow chart of the consensus process.






























administration systems, are available  for  IA use  [26]. 
However,  differences  in  the  use  of  IA  injections  has 
led  to  discordant  recommendations  being  made  in 









Summary of recommendations in which a consensus was reached for agreement
Recommendations (%)
IA injection therapy is useful in patients with hip OA 69.2
IA injection therapy is useful in patients with knee OA 100.0
IA injection therapy is useful in patients with shoulder OA* 69.2
IA injection therapy is useful in patients with ankle OA* 71.2
IA injection therapy is useful in patients with mild to moderate OA 88.5
The choice of drug/medical device to be used is influenced by their safety profile 90.4
The choice of drug/medical device to be used is influenced by their rapid action on symptom relief 74.5
The choice of drug/medical device to be used is influenced by the long-term maintenance of results 90.4
The choice of drug/medical device to be used is influenced by their interaction with other therapies 82.7
The choice of drug/medical device to be used is influenced by their scientific evidences 86.5
High molecular weight HA is adequate for IA injection therapy in patients with hip OA 82.0
Mobile Reticulum HA is adequate for IA injection therapy in patients with hip OA 68.0
Medium molecular weight HA is adequate for IA injection therapy in patients with knee OA 69.2
High molecular weight HA is adequate for IA injection therapy in patients with knee OA 80.8
Cross-linked HA is adequate for IA injection therapy in patients with knee OA 70.6
Mobile Reticulum HA is adequate for IA injection therapy in patients with knee OA 78.0
5 IA injections (1/week) of Low molecular weight HA are useful for early/mild stages of OA* 67.3
1 to 5 IA injections (1/week) of Medium molecular weight HA are useful for early/mild stages of OA 68.0
2 to 3 IA injections (1/week) of High molecular weight HA are useful for early/mild stages of OA* 69.2
1 to 2 IA injections (1/week) of Mobile Reticulum HA are useful for early/mild stages of OA 68.0
Costs determine the lack of use of adequate drugs/medical devices for IA injection therapy of OA 70.0
Minor adverse events are rare (≥1/10.000 a <1/1.000)* 69.2
Major adverse events are rare (≥1/10.000 a <1/1.000) 82.0
IA injection therapy is useful in management of OA 96.0
IA injection therapy with steroids is effective on symptoms relief in patients with OA* 78.8
IA injection therapy with HA is effective on symptoms relief in patients with OA 80.0
IA injection therapy with HA is effective to control objective signs in patients with OA 78.0
IA injection therapy with high molecular weight HA help to delay/avoid joint prosthetic implants 68.0
IA injection therapy with Mobile Reticulum HA help to delay/avoid joint prosthetic implants 67.3
IA injection therapy with high molecular weight HA help to reduce systemic NSAIDs/analgesics consumption 80.0
IA injection therapy with cross-linked HA help to reduce systemic NSAIDs/analgesic drugs consumption 67.3
IA injection therapy with Mobile Reticulum HA help to reduce systemic NSAIDs/analgesics consumption 75.0
Private medical surgery is an appropriate setting to practice IA injection therapies 81.6
Ambulatory is an appropriate setting to practice IA injection therapies 91.8
Hospitals are appropriate settings to practice IA injection therapies 81.6
Ultrasound/ radiologic guide is useful to perform hip IA injections 100.0
IA: intra-articular; OA: osteoarthritis; HA: hyaluronic acid; NSAIDs: non-steroidal anti-inflammatory drugs.
*Recommendations derived from Q2.

































tions  are  not  useful  in  cervical  and  lumbar  spine OA 
patients. A consensus was not reached, both for agree-
ment  nor  disagreement  in  other  sites,  usually  treated 
with  IA  injection  therapies,  like  trapeziometacarpal 
joint [29]. To assess the grade of OA, in our question 
we  referred  to  the  Kellgren  and  Lawrence  classifica-
tion [30], which  is a widely used classification system 
based on X-ray images. Our experts found that IA in-
jections are  suitable  for grade  II/III OA as diagnosed 
according  to  the Kellgren and Lawrence classification 
(i.e. grade II = definite osteophytes and possible  joint 
space  narrowing  on  radiograph;  grade  III  =  multiple 
osteophytes,  definite  joint  space  narrowing,  sclerosis, 
possible bony deformity). This finding further supports 
the role of non-surgical management in lower grades of 
OA, particularly  in view of  the  fact  that patients with 
Kellgren and Lawrence grades ≤ III usually have poorer 
outcomes  following  surgery  [31, 32]. Although  it was 
not  possible  to  reach  an  agreement  on  the  use  of  IA 
injections in low grade OA (grade 0-I), it is noteworthy 







To  select  the most  appropriate  therapeutic  product 
for IA injection therapy, the main variables taken into 
account  by  the  experts  in  this  survey were  the  safety 
profile,  rapid  symptom  relief,  long-term  effect,  inter-
action with  other  therapies  and  scientific  evidence  of 
efficacy.  Interestingly,  the  cost  of  therapy  is  not  con-
sidered among the factors that determine the choice of 
the drug/medical device. However, a subsequent ques-
tion  shows  that  the main  reason  for not  always using 
the most suitable product for treatment is its cost. This 
is  particularly  relevant  to  Italy, where  some drugs  are 
either free or subsidized, while others are not covered 








Summary of recommendations in which a consensus was reached for disagreement 
Recommendations (%)
IA injection therapy is useful in patients with cervical spine OA 78.8
IA injection therapy is useful in patients with lumbar spine OA 71.2
Low molecular weight HA is adequate for IA injection therapy in patients with hip OA* 71.2
Polymerized collagen is adequate for IA injection therapy in patients with knee OA* 67.3
Homotoxicology products are adequate for IA injection therapy in patients with hip OA 70.0
Homotoxicology products are adequate for IA injection therapy in patients with knee OA 72.5
5 to 10 IA injections (1/week) Homotoxicology products are useful for early/mild stages of OA 66.0
Minor adverse events are very common (≥1/10) 88.0
Minor adverse events are common (≥1/100 a <1/10) 75.5
Major adverse events are very common (≥1/10) 95.8
Major adverse events are common (≥1/100 a <1/10) 95.8
Pain after IA injection is one of the most frequent minor adverse event 75.0
Sepsis after IA injection is one of the most frequent major adverse event 72.9
Thromboembolism after IA injection is one of the most frequent major adverse event 83.3
IA injection therapy with homotoxicology products is effective on symptoms relief in patients with OA 69.9
IA injection therapy with homotoxicology products is effective to control objective signs in patients with OA 79.6
IA injection therapy with homotoxicology products help to delay/avoid joint prosthetic implants 73.3
IA injection therapy with homotoxicology products help to reduce systemic NSAIDs/analgesics consumption 71.4
Antibiotic prophylaxis is necessary in case of IA injection therapy 96.0
For IA injection therapy is appropriate to use sterile medical gloves 73.5
Ultrasound/radiologic guide is useful to perform knee IA injections 77.4
IA: intra-articular; OA: osteoarthritis; HA: hyaluronic acid; NSAIDs: non-steroidal anti-inflammatory drugs. 
*Recommendations derived from Q2




























































tary  medicines  tended  to  differ  from  those  who  con-
sulted physicians who prescribe “conventional” therapies 
[35]. This appears to indicate that there is little overlap 
between  these  two  approaches. Any  choice  of  therapy 
should  clearly  be  based  on  strong  evidence  of  efficacy 
















Treatment efficacy  
The  results  of  the  present  survey  indicate  that  Ital-
ian  experts  are  generally  satisfied  with  the  IA  injec-

































indicate  that  precautions  adopted by medical  staff  to 




that  it has been  recently demonstrated  that  some ad-
ditional practices, such as the use of ultrasound probes 
and  transmission  gel  during  ultrasound-guided proce-
dures, result in greater skin contamination during simu-













































The  present  results  are  based  on  a  Delphi  method-
based  survey,  and  thus  reflect  the  current  opinion of  a 
sample of doctors with a high level of expertise who work 
in the field of IA injection therapy for OA in Italy. The 
use of  the Delphi method was  justified  in this case be-


















two  thirds of  responses,  therefore being considered ac-
ceptable for the purposes of the present research. 
In conclusion, this Delphi method-based survey has 
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